Navigation Links
Sinapis Pharma Announces Frederick Frank as Consultant
Date:9/8/2009

JACKSONVILLE, Fla., Sept. 8 /PRNewswire/ -- Sinapis Pharma, Inc is pleased to announce the addition of Frederick Frank as a consultant to the company. Mr. Frank will leverage his decades of experience to advise the company on merger and acquisition opportunities and fund raising for clinical trial development. Sinapis Pharma has discovered and is patenting a new therapeutic approach to treating stroke in humans using Methamphetamine in an intravenous (IV) formulation.

Mr. Frank will advise Sinapis on its M & A corporate development efforts to find a merger partner for Sinapis as the company conducts its Proof of Concept clinical trial. Sinapis is in discussions with potential pharma partners to form a collaboration that will provide Sinapis funding for its Phase I and IIA clinical trials, while granting the right to acquire Sinapis if the two trials are successful. Sinapis management estimates that the Phase IIA Proof of Concept clinical trial will be complete within approximately twenty-eight (28) months.

Mr. Frank is former Vice Chairman of Lehman Brothers where he spent thirty years building the premier big pharma and healthcare investment banking practice in the U.S. and Europe. Mr. Frank is the leading investment banker internationally for pharmaceutical company mergers, acquisitions and equity fund raising.

Sinapis Pharma, Inc (www.sinapispharma.com) is an early stage drug development company whose lead compound methamphetamine, as an intravenous infusion for the treatment of acute stroke and brain injury, has shown robust pre-clinical efficacy. It is a powerful neuroprotective agent with a remarkable 12 hour therapeutic window in animal studies of stroke. Sinapis CEO Donald Picker, Ph.D. states: "We are thrilled to have Fred Frank join our team at Sinapis. His creativity and depth of relationships in the pharmaceutical industry will be invaluable as we execute our development plan."

For more information contact Dr. Picker at Don.Picker@gmail.com.


'/>"/>
SOURCE Sinapis Pharma, Inc
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sinapis Pharma To Present at Rodman & Renshaw Conference
2. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
3. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
4. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
5. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
6. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
7. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
8. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
9. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
10. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
11. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... Las Vegas, NV (PRWEB) , ... May 02, ... ... with Specialty Pharmacy Times, has announced a new Specialty Pharmacy Patient Satisfaction Award ... be determined based on the quarterly results from Zitter Health Insights’ Specialty Pharmacy ...
(Date:5/2/2016)... , ... May 02, 2016 ... ... report that many commonly used prescription medications, including anxiolytics, painkillers, antidepressants and ... these risks, Novus Medical Detox Center —a leading Florida-based drug treatment ...
(Date:5/2/2016)... ... May 02, 2016 , ... TeleMedCo™, a new company developing ... and improve the rapid diagnosis, triage and admission of patients leveraging IBM Watson’s ... mobile experience for the first time at GENBAND’s Perspectives16 conference. , TeleMedCo ...
(Date:5/2/2016)... ... May 02, 2016 , ... Atlantic Information Services, Inc. (AIS) is pleased to ... Could Transform the Pharma Landscape .” CMS recently proposed a test of alternate payment ... drugs while preserving care provided to beneficiaries. The webinar will review the details of ...
(Date:5/2/2016)... ... May 02, 2016 , ... The debilitating disease of arthritis ... With no cure, most patients must deal with prescription costs to treat arthritis over ... up to 75% savings at the pharmacy on many common prescriptions. , Arthritis , ...
Breaking Medicine News(10 mins):
(Date:5/2/2016)... , May 2, 2016  Deerfield announced ... financing of Graybug Vision, Inc. Graybug Vision is ... therapies that may transform care for ocular diseases ... Graybug Vision,s technology was first developed at Johns ... a startup venture. Graybug Vision ...
(Date:4/29/2016)... April 29, 2016  In the next ten ... shift from systems dependent on CRTs monitors to those ... modality CRT Medical monitors and will automatically sync ... host of foreseeable benefits to this technological advancement, ... modalities have to be replaced in order to ...
(Date:4/29/2016)... , April 29, 2016 ... glyco-biology expertise, today announces the appointment of Dr. ... Dr. Zurlo is an oncologist with many years clinical ... and biotechnology industries. His last role was at Mologen ... of the Executive Board. Previously Dr. Zurlo held various ...
Breaking Medicine Technology: